E. Chouinard

755 total citations
12 papers, 424 citations indexed

About

E. Chouinard is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, E. Chouinard has authored 12 papers receiving a total of 424 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Cancer Research. Recurrent topics in E. Chouinard's work include Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer-related cognitive impairment studies (3 papers). E. Chouinard is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer-related cognitive impairment studies (3 papers). E. Chouinard collaborates with scholars based in Canada, United States and Austria. E. Chouinard's co-authors include Stephen D. Walter, Leonard Reyno, Susan Dent, Andrew R. Willan, Amiram Gafni, Mark Levine, K. Pritchard, Timothy J. Whelan, Richard Tozer and Carol Sawka and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

E. Chouinard

12 papers receiving 406 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Chouinard Canada 5 180 143 131 97 91 12 424
Reginald C. S. Ho United States 9 205 1.1× 161 1.1× 187 1.4× 50 0.5× 229 2.5× 19 620
Paula Trahan Rieger United States 13 221 1.2× 101 0.7× 53 0.4× 115 1.2× 128 1.4× 45 652
Raghid Charara Lebanon 8 233 1.3× 73 0.5× 83 0.6× 36 0.4× 59 0.6× 15 512
Simran Padam United States 7 266 1.5× 59 0.4× 133 1.0× 38 0.4× 166 1.8× 16 572
Miguel González Vélez United States 6 150 0.8× 51 0.4× 91 0.7× 34 0.4× 176 1.9× 18 430
Catherine Bender United States 10 162 0.9× 77 0.5× 45 0.3× 48 0.5× 102 1.1× 16 462
Rachel Yang United States 13 198 1.1× 45 0.3× 55 0.4× 62 0.6× 84 0.9× 34 554
Elyse Reamer United States 12 64 0.4× 119 0.8× 92 0.7× 71 0.7× 34 0.4× 14 387
Benjamin Barnes Germany 13 257 1.4× 37 0.3× 63 0.5× 52 0.5× 121 1.3× 29 530
Elham Hedayati Sweden 12 165 0.9× 28 0.2× 111 0.8× 49 0.5× 79 0.9× 44 438

Countries citing papers authored by E. Chouinard

Since Specialization
Citations

This map shows the geographic impact of E. Chouinard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Chouinard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Chouinard more than expected).

Fields of papers citing papers by E. Chouinard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Chouinard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Chouinard. The network helps show where E. Chouinard may publish in the future.

Co-authorship network of co-authors of E. Chouinard

This figure shows the co-authorship network connecting the top 25 collaborators of E. Chouinard. A scholar is included among the top collaborators of E. Chouinard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Chouinard. E. Chouinard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Dent, Susan, et al.. (2018). Abstract P3-15-02: Treat ER+ight Canadian prospective observational study in HR+ advanced breast cancer: 2nd interim analysis. Cancer Research. 78(4_Supplement). P3–15. 1 indexed citations
2.
Rugo, Hope S., Kathleen I. Pritchard, Michael Gnant, et al.. (2014). Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annals of Oncology. 25(4). 808–815. 93 indexed citations
3.
4.
Perez, Alejandra, Hope S. Rugo, José Baselga, et al.. (2013). Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). 558–558. 3 indexed citations
5.
Yardley, Denise A., Gabriel N. Hortobágyi, Fabienne Lebrun, et al.. (2013). Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology. 31(26_suppl). 155–155. 2 indexed citations
6.
Yardley, Denise A., Gabriel N. Hortobágyi, Fabienne Lebrun, et al.. (2013). Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). 553–553. 3 indexed citations
7.
Rugo, Hope S., J. Thaddeus Beck, José Baselga, et al.. (2012). BOLERO-2: Health-related quality-of-life (HRQoL) in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane.. Journal of Clinical Oncology. 30(27_suppl). 125–125. 3 indexed citations
8.
Hirte, Hal W., David J. Stewart, Rakesh Goel, et al.. (2005). An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Investigational New Drugs. 23(5). 437–443. 4 indexed citations
9.
Goel, Rakesh, E. Chouinard, David J. Stewart, et al.. (2004). An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin. Investigational New Drugs. 23(1). 63–71. 6 indexed citations
10.
Whelan, Timothy J., Carol Sawka, Mark Levine, et al.. (2003). Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer. JNCI Journal of the National Cancer Institute. 95(8). 581–587. 185 indexed citations
11.
Chouinard, E. & Stephen D. Walter. (1995). Recall bias in case-control studies: An empirical analysis and theoretical framework. Journal of Clinical Epidemiology. 48(2). 245–254. 48 indexed citations
12.
Chouinard, E., et al.. (1994). Reproducibility of pathological grading in breast cancer. The Breast. 3(2). 124–129. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Reginald C. S. Ho Breakdown of academic impact, for papers by Paula Trahan Rieger Breakdown of academic impact, for papers by Raghid Charara Breakdown of academic impact, for papers by Simran Padam Breakdown of academic impact, for papers by Miguel González Vélez Breakdown of academic impact, for papers by Catherine Bender Breakdown of academic impact, for papers by Rachel Yang Breakdown of academic impact, for papers by Elyse Reamer Breakdown of academic impact, for papers by Benjamin Barnes Breakdown of academic impact, for papers by Elham Hedayati
Rankless by CCL
2026